BillionToOne Overview
- Year Founded
-
2016
- Status
-
Public
- Employees
-
713
- Stock Symbol
-
BLLN
- Share Price
-
$105.15
- (As of Friday Closing)
BillionToOne General Information
Description
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
Contact Information
Website
www.billiontoone.comCorporate Office
- 1035 O'Brien Drive
- Menlo Park, CA 94025
- United States
Corporate Office
- 1035 O'Brien Drive
- Menlo Park, CA 94025
- United States
BillionToOne Timeline
BillionToOne Stock Performance
As of 13-Nov-2026, BillionToOne’s stock price is $105.15. Its current market cap is $5.02B with 47.8M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $105.15 | $110.91 | $61.96 - $150.44 | $5.02B | 47.8M | 605K | $1.07 |
BillionToOne Financials Summary
As of 30-Sep-2026, BillionToOne has a trailing 12-month revenue of $437M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 4,617,881 | 4,078,110 | ||
| Revenue | 436,870 | 305,112 | 152,582 | 71,729 |
| EBITDA | 45,166 | 12,011 | (33,286) | (76,395) |
| Net Income | 49,392 | 7,454 | (41,570) | (82,683) |
| Total Assets | 760,490 | 632,654 | 302,059 | 191,677 |
| Total Debt | 140,448 | 108,895 | 109,376 | 146,346 |
BillionToOne Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
BillionToOne Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
BillionToOne Comparisons
Industry
Financing
Details
BillionToOne Competitors (6)
One of BillionToOne’s 6 competitors is Foundation Medicine, a Formerly VC-backed company based in Boston, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Foundation Medicine | Formerly VC-backed | Boston, MA | ||||
| Myriad Genetics | Corporation | Salt Lake City, UT | ||||
| Guardant Health | Formerly VC-backed | Palo Alto, CA | ||||
| Natera | Formerly VC-backed | Austin, TX | ||||
| Tempus AI | Formerly VC-backed | Chicago, IL |
BillionToOne Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
BillionToOne Patents
BillionToOne Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260325567-A1 | Increasing sensitivity of liquid biopsies with pre-application of a dnase1l3 inhibitor agent | Pending | 21-Apr-2025 | ||
| WO-2026226540-A1 | Increasing sensitivity of liquid biopsies with pre-application of a dnase1l3 inhibitor agent | Pending | 21-Apr-2025 | ||
| WO-2026222337-A1 | Tumor-naive tumor fraction measurement at sub-molecule limit of detection | Pending | 16-Apr-2025 | ||
| US-20260327716-A1 | Tumor-naïve tumor fraction measurements at sub-molecule limit of detection | Pending | 16-Apr-2025 | ||
| US-20260139303-A1 | Load balancing of primers in multiplex pcr | Pending | 20-Nov-2024 | C12Q1/6851 |
BillionToOne Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
BillionToOne ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Healthcare
Industry
Rank
Percentile
Medical Services
Subindustry
Rank
Percentile
BillionToOne FAQs
-
When was BillionToOne founded?
BillionToOne was founded in 2016.
-
Where is BillionToOne headquartered?
BillionToOne is headquartered in Menlo Park, CA.
-
What is the size of BillionToOne?
BillionToOne has 713 total employees.
-
What industry is BillionToOne in?
BillionToOne’s primary industry is Diagnostic Equipment.
-
Is BillionToOne a private or public company?
BillionToOne is a Public company.
-
What is BillionToOne’s stock symbol?
The ticker symbol for BillionToOne is BLLN.
-
What is the current stock price of BillionToOne?
As of 13-Nov-2026 the stock price of BillionToOne is $105.15.
-
What is the current market cap of BillionToOne?
The current market capitalization of BillionToOne is $5.02B.
-
What is BillionToOne’s current revenue?
The trailing twelve month revenue for BillionToOne is $437M.
-
Who are BillionToOne’s competitors?
Foundation Medicine, Myriad Genetics, Guardant Health, Natera, and Tempus AI are some of the 6 competitors of BillionToOne.
-
What is BillionToOne’s annual earnings per share (EPS)?
BillionToOne’s EPS for 12 months was $1.07.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
